Egypt’s Parkinson’s Disease drugs market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Parkinson’s disease is the combination of progressive, degenerative neurological motor disorder, mainly affecting the dopaminergic cells of the brain. Tremor, rigidity, bradykinesia, and postural volatility are some of the common symptoms of Parkinson’s disease.
Presently, only symptomatic drug treatments are available in the market. Moreover, these symptoms are diagnosed at later stages when most of the dopamine-producing cells have lost their function. This scenario indicates an impending need for innovative drugs. Overall, the drug market has witnessed tremendous growth due to rising cases.
The overall prevalence of Parkinson’s disease is high in the Nile valley governorates of Upper Egypt compared to other Arabic countries.
The high growth in the aging population and the coupled increase in the prevalence of Parkinson’s disease are amongst the important factors intensifying the growth and demand of the Parkinson’s disease treatment market. Egypt’s geriatric population will constitute about 7% percent of its population by 2030.
Further, the research funding for the disease too has increased, propelling the growth for the treatment market of Parkinson’s.